Market Overview

JP Morgan Says Jazz Pharmaceuticals Positioned For 'Organic Growth And Acquisition'

Share:
Related JAZZ
The Wall Street Research Making Waves Today
Jazz Pharma Could Be Worth Over $200 If Xyrem Adds Long-Term Value: Here's How
Biogen Wins Round In Patent Fight Vs. Kyle Bass (Investor's Business Daily)

Shares of Jazz Pharmaceuticals (NASDAQ: JAZZ) are up almost 20 percent over the past five trading sessions.

JP Morgan started coverage of the company with an Overweight rating and $190 price target.

"In the context of an ongoing wave of consolidation in the specialty pharmaceuticals sector, we see Jazz as well positioned from both an organic growth and acquisition standpoint," writes analyst Jessica Fye.

Related Link: Leerink Says Tekmir Is 'Uniquely Positioned'

JP Morgan further comments that the company is diversifying away from from its core asset with acquisitions. The company has a borrowing allowance of $3 billion.

On Tuesday, Dow Jones reported Allergan (NYSE: AGN) is interested in purchasing Salix Pharmaceuticals (NASDAQ: SLXP), a competitor in the acquisition space. This news moved Jazz almost four percent higher to $158.14.

Latest Ratings for JAZZ

DateFirmActionFromTo
Jul 2015Leerink SwannMaintainsOutperform
Jun 2015UBSMaintainsBuy
May 2015Leerink SwannMaintainsOutperform

View More Analyst Ratings for JAZZ
View the Latest Analyst Ratings

Posted-In: Jessica Fye JP MorganAnalyst Color Price Target Initiation Analyst Ratings

 

Related Articles (JAZZ + AGN)

Get Benzinga's Newsletters